Evaluation of the Persistent Preventive Efficacy of 2.5 % Moxidectin/10 % Imidacloprid Spot-on (Advocate®, Advantage® Multi) in Dogs Experimentally Infected with Angiostrongylus vasorum

Abstract

A controlled, randomized and blinded doseconfirmation study was conducted to assess the persistent preventive efficacy of treatment with Advocate spot-on (2.5 % moxidectin / 10 % imidacloprid) in dogs four weeks before inoculation of third-stage larvae of Angiostrongylus (A.) vasorum. Twenty-four adult dogs were randomly allocated to three treatment groups. Dogs in group 1 were treated with Advocate spot-on at the minimum recommended dose of 0.1 mL per kg bodyweight (BW) on day 84 and inoculated with third-stage larvae of A. vasorum on day 112. Dogs in group 2 were treated monthly with Advocate spot-on on days 0, 28, 56 and 84 at the minimum recommended dose of 0.1 mL per kg BW and inoculated